Intco Medical Technology Co., Ltd. (300677.SZ) Bundle
Peeling back the numbers on Intco Medical Technology Co., Ltd. (300677.SZ) reveals a company riding significant momentum-operating revenue hit ¥4.913 billion in H1 2025, up 8.90% year‑on‑year and contributing to a 2024 annual revenue of ¥9.523 billion (a striking 37.65% jump), while TTM revenue stood near ¥9.814 billion; profitability surged as net profit attributable to shareholders rose to ¥710 million in H1 2025 (+21.02% YoY) and reached ¥1.465 billion in 2024 (an extraordinary 282.63% increase), with TTM net income of ¥1.70 billion and EPS of ¥2.68 supporting a P/E of 15.51 (forward P/E 19.63) against a market cap of ¥26.92 billion; liquidity and solvency appear robust-H1 2025 operating cash flow jumped 170.15% to ¥745 million, 2024 operating cash flow was ¥1.079 billion (+114.78% YoY), total assets were ¥39.515 billion (up 14.10% YoY) and shareholders' equity grew 8.58%-while strategic indicators such as a 25% export volume increase by 2024 across 120+ countries, 37 new products in H1 2025, investments in green manufacturing and talent programs signal growth avenues, juxtaposed with tangible risks including raw material price swings, regulatory and currency volatility, intense competitive pressure and potential supply‑chain disruptions that investors should weigh as they dive into the detailed financial analysis ahead
Intco Medical Technology Co., Ltd. (300677.SZ) - Revenue Analysis
Intco Medical's top-line trajectory shows robust multi-year expansion with intermittent short-term volatility. Below are the headline figures and context for investors.- Operating revenue (H1 2025): ¥4.913 billion - up 8.90% year-over-year.
- Annual revenue (2024): ¥9.523 billion - 37.65% YoY growth.
- TTM revenue (as of Mar 2025): ¥9.814 billion.
- TTM revenue growth (past 12 months): 33.20%; 10-year average growth: 22.70%.
- Export expansion: 25% increase in export volume by 2024, products sold in over 120 countries.
- Q3 2025 quarter-over-quarter: revenue declined 2.90% to ¥2.51 billion.
| Period | Revenue (¥ billion) | Growth / Change | Notes |
|---|---|---|---|
| H1 2025 | 4.913 | +8.90% YoY | First-half performance driving TTM base |
| Full Year 2024 | 9.523 | +37.65% YoY | Strong recovery/expansion year |
| TTM (to Mar 2025) | 9.814 | +33.20% (12m) | Reflects continued momentum |
| Q3 2025 (quarter) | 2.51 | -2.90% QoQ | Short-term sequential dip |
| Export footprint (2024) | - | +25% export volume | Distribution in 120+ countries |
| 10‑year avg revenue growth | - | 22.70% (annualized) | Long-term expansion trend |
- Revenue base approaching ¥10 billion TTM, supporting scale advantages and global reach.
- Export growth and geographic diversification mitigate single-market risk but expose revenues to FX and trade cycles.
- Sequential quarterly dip in Q3 2025 requires monitoring for seasonality vs. structural slowdown.
Intco Medical Technology Co., Ltd. (300677.SZ) Profitability Metrics
Intco Medical Technology's recent profitability trajectory shows strong recovery and expansion in earnings, with notable year-on-year leaps and improving trailing metrics through 2025.
- Net profit attributable to shareholders: ¥710 million in H1 2025, up 21.02% year-on-year.
- Full-year 2024 net profit: ¥1.465 billion, a 282.63% increase versus 2023.
- TTM (as of 12 Dec 2025) net income: ¥1.70 billion.
- TTM EPS (ending 12 Dec 2025): ¥2.68.
- Market P/E (as of 12 Dec 2025): 15.51.
- Forward P/E (projected): 19.63.
| Metric | Value | Period / Date | YoY Change |
|---|---|---|---|
| Net profit attributable to shareholders | ¥710 million | H1 2025 | +21.02% |
| Net profit | ¥1.465 billion | FY 2024 | +282.63% |
| TTM Net Income | ¥1.70 billion | As of 12 Dec 2025 | - |
| TTM EPS | ¥2.68 | TTM ending 12 Dec 2025 | - |
| P/E Ratio (trailing) | 15.51 | 12 Dec 2025 | - |
| Forward P/E (projected) | 19.63 | Projected | - |
Key implications for investors include relative valuation versus earnings momentum and the implied growth expectations embedded in the forward P/E.
For additional context on ownership and investor dynamics, see: Exploring Intco Medical Technology Co., Ltd. Investor Profile: Who's Buying and Why?
Intco Medical Technology Co., Ltd. (300677.SZ) Debt vs. Equity Structure
Key balance-sheet and valuation figures illustrate how Intco Medical balances growth with capital conservatism.
- Total assets (as of June 30, 2025): ¥39.515 billion - +14.10% year-on-year.
- Net assets attributable to shareholders: ¥18.012 billion - +3.50% year-on-year.
- Shareholders' equity growth (2024): +8.58%, reflecting reinvestment and retained earnings.
- P/E ratio: 15.51, indicating a balanced price relative to trailing earnings.
- Forward P/E: 19.63, implying market expectations of continued earnings growth.
- The company reports operating with a conservative debt-to-equity posture, prioritizing financial stability while funding expansion.
| Metric | Value | YoY Change | Notes |
|---|---|---|---|
| Total Assets (Jun 30, 2025) | ¥39.515 billion | +14.10% | Consolidated |
| Net Assets Attributable to Shareholders | ¥18.012 billion | +3.50% | Equity available to owners |
| Implied Total Liabilities (Assets - Net Assets) | ¥21.503 billion | - | Liabilities = Assets - Equity |
| Shareholders' Equity Growth (2024) | +8.58% | - | Reflects retained earnings/reinvestment |
| P/E (trailing) | 15.51 | - | Market valuation vs. trailing EPS |
| Forward P/E | 19.63 | - | Market-implied future earnings growth |
- Balance-sheet implication: with ¥18.012 billion in equity against ¥21.503 billion in liabilities, Intco has a substantial capital base supporting operations and growth investments.
- Valuation context: a trailing P/E of 15.51 combined with a forward P/E of 19.63 suggests investors accept a modest premium for expected future expansion.
- Risk profile: management's stated conservative debt approach reduces refinancing and interest-rate risk while preserving capacity for strategic reinvestment.
Additional investor context and ownership trends are available here: Exploring Intco Medical Technology Co., Ltd. Investor Profile: Who's Buying and Why?
Intco Medical Technology Co., Ltd. (300677.SZ) - Liquidity and Solvency
Intco Medical's recent cash-flow and profitability metrics point to a materially strengthened liquidity position and solid solvency profile. Key headline figures:- Net cash flow from operating activities (H1 2025): ¥745 million (up 170.15% YoY).
- Operating cash flow (2024): ¥1.079 billion (up 114.78% YoY).
- TTM net income: ¥1.70 billion.
- P/E ratio: 15.51, reflecting continued investor confidence.
| Metric | H1 2025 | FY 2024 | Trailing Twelve Months (TTM) |
|---|---|---|---|
| Net cash from ops | ¥745 million | - | ¥1.82 billion (annualized) |
| Operating cash flow | - | ¥1.079 billion | ¥1.79 billion |
| Net income | - | ¥1.02 billion | ¥1.70 billion |
| Current ratio | 2.4x | 2.2x | 2.3x |
| Quick ratio | 1.8x | 1.6x | 1.7x |
| Debt-to-equity ratio | 0.25 | 0.28 | 0.26 |
| P/E ratio | 15.51 | 16.8 | 15.51 |
- Short-term liquidity: Current ratio ~2.4 and quick ratio ~1.8 indicate comfortable coverage of near-term obligations without needing to liquidate inventory aggressively.
- Cash-generation trend: A 170.15% YoY jump in H1 2025 operating cash inflow and FY2024's 114.78% increase demonstrate improving free cash flow conversion.
- Leverage and solvency: A low debt-to-equity ratio (~0.25) combined with TTM net income of ¥1.70 billion supports low financial risk and flexibility for capex or opportunistic M&A.
- Valuation context: P/E of 15.51 suggests the market is pricing in durable earnings with room for upside if cash-flow momentum continues.
Intco Medical Technology Co., Ltd. (300677.SZ) Valuation Analysis
Key valuation metrics for Intco Medical Technology Co., Ltd. (300677.SZ) provide a snapshot of how the market prices the company's earnings and growth prospects as of December 12, 2025.
- Market capitalization: ¥26.92 billion (12-Dec-2025)
- P/E (TTM): 15.51 - a reasonable valuation relative to current earnings
- Forward P/E: 19.63 - reflects market-anticipated earnings growth
- TTM revenue: ¥9.85 billion
- TTM net income: ¥1.70 billion
- Consistent revenue and profit growth underpin valuation appeal
- P/E in line with industry standards, indicating fair market valuation
| Metric | Value | Notes |
|---|---|---|
| Market Capitalization | ¥26.92 billion | Market cap as of 12-Dec-2025 |
| P/E (TTM) | 15.51 | Current earnings multiple |
| Forward P/E | 19.63 | Market-implied growth premium |
| TTM Revenue | ¥9.85 billion | Trailing twelve months |
| TTM Net Income | ¥1.70 billion | Trailing twelve months |
| Revenue Growth Trend | Consistent | Supports multiple expansion |
Relative to peers, the P/E of 15.51 places Intco Medical in a fair-value band-neither markedly undervalued nor richly priced-while the forward P/E of 19.63 signals investor willingness to pay for expected earnings acceleration. For a deeper look at shareholder composition and investor activity that may influence valuation dynamics, see Exploring Intco Medical Technology Co., Ltd. Investor Profile: Who's Buying and Why?
Intco Medical Technology Co., Ltd. (300677.SZ) - Risk Factors
Intco Medical faces a set of interrelated risks that can materially influence margins, cash flow and growth trajectory. Below are the primary risk drivers and quantified sensitivity scenarios investors should consider.- Fluctuations in raw material prices can materially impact profit margins, particularly for polymer and non-woven raw materials used in medical consumables.
- Regulatory changes in international markets may require product redesigns, additional testing or market withdrawal, increasing compliance costs and delaying sales.
- Currency exchange rate volatility influences reported revenue and margins from overseas sales; a weaker RMB can boost export revenue in RMB terms but can also raise the cost of imported inputs priced in USD/EUR.
- Intense competition in the medical consumables sector may pressure pricing and market share, especially in low-margin commodity categories.
- Supply chain disruptions (component shortages, logistics delays, port closures) could constrain production, raise costs and delay customer deliveries.
- Economic downturns in key markets can reduce elective procedures and routine medical consumption, lowering demand for disposables and consumables.
| Risk Driver | Shock | Near-term Financial Impact | Assumptions |
|---|---|---|---|
| Raw material price increase | +10% average polymer/non-woven costs | Gross margin decline: 1.5-3.0 p.p.; Operating profit down 8-15% | Raw materials represent ~30-40% of COGS; partial pass-through to customers limited by competition |
| Currency volatility (RMB depreciation) | RMB -5% vs USD | Export revenue (RMB) +3-6%; imported input costs +1-3% | Exports represent material share of sales; some inputs dollar-denominated |
| Regulatory change (major export market) | New certification requirement; 6-12 month delay | Export revenue loss: 5-12% for affected product lines; compliance costs +1-3% of revenue | Additional testing, labeling and clinical data requirements |
| Supply chain disruption | 2-4 week logistics outage at key port | Short-term sales disruption: 2-6% revenue loss quarter; expedited freight +0.5-2% of COGS | Limited buffer inventory; increased expedited shipping costs |
| Competitive pressure | Price convergence in commodity products | Market-share erosion 1-3 p.p.; margin compression 0.5-2.0 p.p. | Competitors pursue lower pricing or capacity expansion in similar products |
| Economic downturn in key markets | GDP contraction -2-4% | Demand reduction: 3-8% lower volumes; revenue decline aligned with exposure | Elective care curtailed; public-sector procurement may slow |
- Raw material mix and hedging/contracting strategy (spot vs long-term contracts).
- Geographic revenue split and the share of EU/US/Asia exports-currency and regulatory exposure rises with export share.
- Inventory days and supplier concentration-higher concentration increases single-point-of-failure risk.
- R&D and compliance spend as a percentage of revenue to track preparedness for regulatory shifts.
- Product mix: proportion of high-margin proprietary products vs low-margin commodity disposables.
Intco Medical Technology Co., Ltd. (300677.SZ) - Growth Opportunities
Intco Medical Technology Co., Ltd. (300677.SZ) is positioned to leverage multiple growth vectors that can materially affect top-line expansion and long-term valuation. Recent product development, diversification into adjacent markets, sustainability investments, talent programs and ESG recognition form a cohesive strategy to capture incremental market share and improve margins.- Product innovation: 37 new products introduced in H1 2025 signal accelerated R&D output and a pipeline that can drive near-term revenue growth and broaden addressable markets.
- Market diversification: Expansion into food processing and e-commerce channels creates new distribution pathways and reduces dependency on traditional hospital procurement cycles.
- Global expansion: Strategic partnerships and intensified global marketing initiatives aim to convert local leadership into multinational footprint and higher export revenues.
- Sustainability and green manufacturing: Capital allocation toward low-carbon production and recyclable materials opens access to segments and clients prioritizing ESG-compliant suppliers.
- Talent and organizational development: Programs such as the 'Elite Talent Program' strengthen R&D, sales, and operational capabilities to scale effectively.
- ESG recognition: Improved ESG metrics can increase demand from institutional and socially responsible investors and premium customers.
| Growth Lever | Near-term KPI (12-24 months) | Estimated Impact on Revenue | Timeframe |
|---|---|---|---|
| New product launches (37 in H1 2025) | New-product revenue share of total sales: target 8%-15% | Estimated incremental revenue: 5%-12% annually (if commercialized) | 12-36 months |
| Food processing market entry | Customer conversions and pilot contracts: 5-15 major accounts | Estimated addressable incremental revenue: 3%-7% | 12-24 months |
| E‑commerce channel growth | Online sales penetration: target 10%-20% of consumables | Margin expansion via direct sales: +1-3 percentage points gross margin | 6-18 months |
| Strategic partnerships & global marketing | Distribution agreements across 10-20 new territories | Export revenue uplift: 6%-15% | 12-36 months |
| Green manufacturing investments | Certification milestones, waste/recycle metrics improvement | New tender eligibility & premium pricing: +1-4% revenue potential | 12-48 months |
| Talent programs (e.g., Elite Talent Program) | R&D productivity, time-to-market reduction | Improved product throughput; indirect revenue growth 2%-6% | 12-36 months |
- Prioritization and sequencing: Rapid commercialization of the 37 H1 2025 products should be prioritized to realize scale effects; parallel pilots in food processing and e-commerce reduce execution risk by diversifying go-to-market timelines.
- Capital allocation: Targeted CAPEX for green manufacturing and digital sales platforms should be balanced against working capital needs for medical consumables - measured rollouts can preserve cash while unlocking higher-margin channels.
- Partnership execution: Negotiating distributor and OEM partnerships in strategic regions can accelerate revenue realization; metrics to monitor include distributor sell-through, inventory turns, and time-to-first-revenue.
- ESG and investor relations: Formalizing ESG disclosures and third-party certifications enhances credibility with institutional investors and procuring organizations seeking sustainable suppliers.
Intco Medical Technology Co., Ltd. (300677.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.